13D Filing: Lansdowne Partners and Summit Therapeutics PLC (ADR) (SMMT)

Page 7 of 8 – SEC Filing

CUSIP No. 86627R102 13D/A

SIGNATURES

After reasonable
inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete
and correct.

Date: January 30, 2018

Lansdowne Partners (UK) LLP /s/ Hugh Orange
Signature
Hugh Orange
Chief Compliance Officer
Lansdowne Developed Markets Master Fund Limited /s/ Hugh Orange
Signature
Hugh Orange
Chief Compliance Officer of its investment adviser

Follow Summit Therapeutics Inc. (NASDAQ:SMMT)